Therapeutic | Spartalizumab |
Target | PDCD1 |
Heavy Chain | EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS |
Light Chain | EIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (October '21) | Phase-II |
Estimated Status (October '21) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2017 |
INN Year Recommended | 2018 |
Companies Involved | Asan Medical Center, Dana-Farber Cancer Institute, Novartis, Novartis Oncology, Palobiofarma, Seoul National University Hospital |
Conditions Approved | na |
Conditions Active | Malignant melanoma, Breast cancer, Colorectal cancer, Diffuse large B cell lymphoma, Gastric cancer, Nasopharyngeal cancer, Non-small cell lung cancer, Solid tumours, Acute myeloid leukaemia, Cancer, Liver cancer, Lymphoma, Multiple myeloma, Myelodysplastic syndromes, Ovarian cancer, Pancreatic cancer, Renal cancer |
Conditions Discontinued | Neuroendocrine tumours |
Notes |
SAbDab papers
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]
Thera-SAbDab paper
Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]